In an unrecruited trial, the immune checkpoint inhibitor pembrolizumab, CD47 inhibitor ALX148, and liposomal doxorubicin were evaluated for safety and efficacy in patients with recurrent platinum-resistant ovarian cancer (NCT05467670). This evidence concerns the gene CD47 and ovarian cancer.